A variety of technology choices are emerging as potential solutions for the identification of mutations in formalin-fixed, paraffin-embedded tumor samples and cell-free DNA for liquid biopsy analysis.

In this on-demand webinar, Dr. Karl Kashofer, head of the diagnostic genome analysis laboratory at the Medical University of Graz, describes an evaluation of digital PCR and targeted next generation sequencing for potential use in biomarker discovery and monitoring of pathology research samples.

Dr. Kashofer details his laboratory’s learnings, including:

• What should you consider when choosing technology for pathology investigations?
• How should you handle data interpretation for rare allele detection in samples with large deletions?
• How do you optimize sensitivity in FFPE and cfDNA samples?
• What are the key differences observed in digital PCR, Ion AmpliSeq, Ion AmpliSeq HD, and Oncomine cfDNA assays?

For research use only. Not for use in diagnostic procedures.